Journal
CLINICAL INFECTIOUS DISEASES
Volume 45, Issue -, Pages S20-S23Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/518135
Keywords
-
Categories
Funding
- NCRR NIH HHS [M01 RR016500] Funding Source: Medline
- NIAID NIH HHS [N01 AI25461, N01 AI40014] Funding Source: Medline
Ask authors/readers for more resources
Typhoid fever remains an important public health problem in many parts of the world. Despite the availability of oral Ty21a (Vivotif; Berna Biotech) and parenteral Vi polysaccharide vaccine (Typhim Vi; Aventis Pasteur), improved typhoid fever vaccines have been sought. These include a series of vaccine candidates developed at the Center for Vaccine Development, University of Maryland, based on attenuation of Salmonella enterica serovar Typhi by deletions in the aroC, aroD, and htrA genes. These vaccine candidates, designated CVD 908, CVD 908-htrA, and CVD 909, have been developed and tested in volunteers with variable success. This review summarizes the clinical data that directed the logical progression of this vaccine development strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available